Rhythm Biosciences バランスシートの健全性

財務の健全性基準チェック /66

Rhythm Biosciencesの総株主資本はA$867.2K 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$1.5MとA$651.5Kです。

主要情報

負債資本比率

AU$0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	AU$754.50k
エクイティ	AU$867.17k
負債合計	AU$651.54k
総資産	AU$1.52m

財務の健全性に関する最新情報

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Recent updates

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

Dec 06

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Aug 09

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Apr 11

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

財務状況分析

短期負債: RHYの短期資産 ( A$886.7K ) が短期負債 ( A$561.8K ) を超えています。

長期負債: RHYの短期資産 ( A$886.7K ) が長期負債 ( A$89.7K ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: RHYは負債がありません。

負債の削減: RHY 5 年前には負債がありませんでした。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: RHYは、前回報告されたフリーキャッシュフローに基づいて1か月分の十分なキャッシュランウェイを有していますが、その後追加の資本を調達しました。

キャッシュランウェイの予測: RHYフリーキャッシュフロー推定値に基づいて1か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。

Rhythm Biosciences バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Recent updates

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /66